Literature DB >> 7235418

Spectrum of pheochromocytoma in multiple endocrine neoplasia. A scintigraphic portrayal using 131I-metaiodobenzylguanidine.

T W Valk, M S Frager, M D Gross, J C Sisson, D M Wieland, D P Swanson, T J Mangner, W H Beierwaltes.   

Abstract

Six patients with multiple endocrine neoplasia (MEN) types 2a and 2b were investigated to determine the spectrum of pheochromocytoma by scintigraphy. Iodine-131-metaiodobenzylguanidine (131I-MIBG), a new imaging agent which concentrates in adrenergic neurotransmitter vesicles, was administered at 0.5 mCi/1.7m2 and scintiscans were taken at 24 and 48 hours. Two normotensive patients with normal plasma and urinary catecholamines had no adrenal tracer uptake. One patient with a modest and intermittent increase only in urinary catecholamine metabolites showed faint adrenal images. Two other patients with increased plasma and urinary catecholamines showed bilateral adrenal imaging patterns. The sixth patient who had increased norepinephrine and epinephrine secretion showed bilateral asymmetrical adrenal images, findings that were corroborated at operation. Functional as well as anatomic evidence of adrenal medullary abnormalities in patients with MEN-2 syndromes are demonstrated by 131I-MIBG scintigraphy. Therefore, the procedure can be used to define the extent of abnormalities of the adrenal medulla in these patients.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7235418     DOI: 10.7326/0003-4819-94-6-762

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  19 in total

1.  Multiple endocrine neoplasia type 2 with malignant pheochromocytoma--long term follow-up of a case by 131I-meta-iodobenzylguanidine scintigraphy.

Authors:  H Namba; H Kondo; S Yamashita; H Kimura; N Yokoyama; M Tsuruta; A Sato; M Izumi; H Kinoshita; S Hakariya
Journal:  Ann Nucl Med       Date:  1992-05       Impact factor: 2.668

Review 2.  Diagnostic problems in pheochromocytoma.

Authors:  M Mannelli
Journal:  J Endocrinol Invest       Date:  1989-11       Impact factor: 4.256

3.  Surgical management of the adrenal glands in the multiple endocrine neoplasia type II syndrome.

Authors:  J A van Heerden; G W Sizemore; J A Carney; C S Grant; W H ReMine; S G Sheps
Journal:  World J Surg       Date:  1984-08       Impact factor: 3.352

4.  Extra-adrenal and metastatic pheochromocytoma: the role of 131I meta-iodobenzylguanidine (131I MIBG) in localization and management.

Authors:  N W Thompson; M D Allo; B Shapiro; J C Sisson; W Beierwaltes
Journal:  World J Surg       Date:  1984-08       Impact factor: 3.352

5.  Spectrum of pheochromocytoma in the 131I-MIBG era.

Authors:  P S Cheung; N W Thompson; C F Dmuchowski; J C Sisson
Journal:  World J Surg       Date:  1988-08       Impact factor: 3.352

6.  Long-term course and cardiac sympathetic nerve activity in patients with hypertrophic cardiomyopathy.

Authors:  M Shimizu; N Sugihara; Y Kita; K Shimizu; Y Horita; K Nakajima; J Taki; R Takeda
Journal:  Br Heart J       Date:  1992-02

Review 7.  Nuclear medicine and multimodality imaging of pediatric neuroblastoma.

Authors:  Wolfgang Peter Mueller; Eva Coppenrath; Thomas Pfluger
Journal:  Pediatr Radiol       Date:  2012-11-14

8.  Usefulness of 123I-MIBG scintigraphy in the evaluation of patients with known or suspected primary or metastatic pheochromocytoma or paraganglioma: results from a prospective multicenter trial.

Authors:  Gregory A Wiseman; Karel Pacak; Mary S O'Dorisio; Donald R Neumann; Alan D Waxman; David A Mankoff; Sherif I Heiba; Aldo N Serafini; Sabah S Tumeh; Natalie Khutoryansky; Arnold F Jacobson
Journal:  J Nucl Med       Date:  2009-08-18       Impact factor: 10.057

9.  Uptake of 131I-MIBG by medullary carcinoma of thyroid in familial cases.

Authors:  G Coutris; J N Talbot; G Kabla; C Calmettes; G Milhaud
Journal:  Eur J Nucl Med       Date:  1986

10.  Management of pheochromocytomas in patients with multiple endocrine neoplasia type 2 syndromes.

Authors:  T C Lairmore; D W Ball; S B Baylin; S A Wells
Journal:  Ann Surg       Date:  1993-06       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.